Analyst consensus rating
Corbus Pharmaceuticals Holdings Analyst Rating: Strong Buy
Direct answer
Corbus Pharmaceuticals Holdings's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $32.67.
Forecast evidence checked November 22, 2026.
Get free Corbus Pharmaceuticals Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.06
- Average price target
- $32.67
- High price target
- $45.00
- Low price target
- $23.00
- Low target gap
- +1,016.5%
- Target upside
- +1,485.8%
- High target gap
- +2,084.5%
- Target range width
- 1,068%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- November 22, 2026
- Valid through
- November 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Corbus Pharmaceuticals Holdings?
Corbus Pharmaceuticals Holdings has a verified Strong Buy consensus. The same dataset has an average price target of $32.67.
How far are Corbus Pharmaceuticals Holdings's low and high targets from the recorded price?
The low target implies +1,016.5%, while the high target implies +2,084.5%.
How many analysts are included in Corbus Pharmaceuticals Holdings's consensus?
The verified consensus includes 9 analysts.
How is Corbus Pharmaceuticals Holdings's target upside or downside calculated?
The average target of $32.67 is divided by the recorded price of $2.06, then one is subtracted to produce +1,485.8%. This does not guarantee a future return.
When was Corbus Pharmaceuticals Holdings's analyst forecast verified?
The data was verified on 2026-11-22. The dataset is valid through 2026-11-29.